Clinical trial · no report yet · Phase 3
OPTIMISMM
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- NCT01734928 ↗
- Completed
- Celgene
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 16 | |
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide; Bortezomib; Dexamethasone
- Arms
- Pomalidomide, Bortezomib and Low Dose Dexamethasone · Experimental
- Bortezomib and Low Dose Dexamethasone · Active comparator
- Enrollment
- 559
- Primary outcomes
- Progression Free Survival by Independent Response Adjudication Committee (IRAC)
- Sponsor
- Celgene
- Start
- Jan 7, 2013
- Primary completion
- May 9, 2022
- Results posted
- Yes
- Registry record
- NCT01734928 · updated Jun 6, 2023
Publications
linked from the registry- Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. PubMed 31097405
- Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017 Dec;31(12):2695-2701. doi: 10.1038/leu.2017.173. Epub 2017 Jun 2. PubMed 28642620